J
Julia Amaranta Garcia-Fuertes
Publications - 2
Citations - 230
Julia Amaranta Garcia-Fuertes is an academic researcher. The author has contributed to research in topics: Culture conversion & Bedaquiline. The author has an hindex of 2, co-authored 2 publications receiving 167 citations.
Papers
More filters
Journal ArticleDOI
Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study
Sergey Borisov,Keertan Dheda,Martin Enwerem,Rodolfo Romero Leyet,Lia D'Ambrosio,Rosella Centis,Giovanni Sotgiu,Simon Tiberi,Simon Tiberi,Jan-Willem C. Alffenaar,Andrey Maryandyshev,Evgeny Belilovski,Shashank Ganatra,Alena Skrahina,Onno W. Akkerman,Alena Aleksa,Rohit Amale,Janina Artsukevich,Judith Bruchfeld,Jose A. Caminero,Isabel Carpena Martinez,Luigi Codecasa,Margareth Pretti Dalcolmo,Justin T Denholm,Paul Douglas,Raquel Duarte,Aliasgar Esmail,Mohammed Fadul,Alexey Filippov,Lina Davies Forsman,Mina Gaga,Julia Amaranta Garcia-Fuertes,José-María García-García,Gina Gualano,Jerker Jonsson,Heinke Kunst,Jillian S.Y. Lau,Barbara Lazaro Mastrapa,Jorge Lazaro Teran Troya,Selene Manga,Katerina Manika,Pablo González Montaner,Jai B Mullerpattan,Suzette Oelofse,Martina Ortelli,Domingo Palmero,Fabrizio Palmieri,Antonella Papalia,Apostolos Papavasileiou,Marie-Christine Payen,Emanuele Pontali,Carlos Robalo Cordeiro,Laura Saderi,Tsetan Dorji Sadutshang,Tatsiana Sanukevich,Varvara Solodovnikova,Antonio Spanevello,Sonam Topgyal,Federica Toscanini,Adrian R Tramontana,Zarir F Udwadia,Pietro Viggiani,Veronica White,Alimuddin Zumla,Giovanni Battista Migliori +64 more
TL;DR: Bedaquiline-containing regimens achieved high conversion and success rates under different nonexperimental conditions, and is safe and effective in treating MDR- and XDR-TB patients.
Proceedings ArticleDOI
Bedaquiline (BQ)-containing regimen at the programmatic level for MDR-TB: preliminary results
Sergey Borisov,Keertan Dheda,Martin Enwerem,Rodolfo Romero Leyet,Lia D'Ambrosio,Rosella Centis,Giovanni Sotgiu,Simon Tiberi,Jan-Willem C. Alffenaar,Andrey Maryandyshev,Evgeny Belilowski,Shashank Ganatra,Alena Skrahina,Onno W. Akkerman,Alena Aleksa,Rohit Amale,Janina Artsukevich,Judith Bruchfeld,Jose A. Caminero,Isabel Carpena Martinez,Luigi Codecasa,Margareth Pretti Dalcolmo,Justin T Denholm,Paul Douglas,Raquel Duarte,Aliasgar Esmail,Mohammed Fadul,Alex Filippov,Lina Davies Forsman,Mina Gaga,Julia Amaranta Garcia-Fuertes,José-María García-García,Gina Gualano,Jerker Jonsson,Heinke Kunst,Jillian S.Y. Lau,Barbara Lazaro Mastrapa,Jorge Lazaro Teran Troya,Selene Manga,Katerina Manika,Pablo González Montaner,Jai B Mullerpattan,Suzette Oelofse,Martina Ortelli,Domingo Palmero,Fabrizio Palmieri,Antonella Papalia,Apostolos Papavasileiou,Marie-Christine Payen,Emanuele Pontali,Carlos Robalo Cordeiro,Tsetan Dorji Sadutshang,Tatsiana Sanukevich,Varvara Solodovnikova,Antonio Spanevello,Sonam Topgyal,Federica Toscanini,Adrian R Tramontana,Zarir F Udwadia,Pietro Viggiani,Veronica White,Alimuddin Zumla,Giovanni Battista Migliori +62 more
TL;DR: The results of this study, the largest ever done, indicate that BQ-containing regimens used at the programmatic level achieve satisfactory outcomes and bacteriological conversion rates even with a significant proportion of XDR-TB cases.